Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07175207

Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis

This study aims to evaluate the safety and efficacy of the umbilical cord blood mononuclear cells (UCB-MNCs) therapy for chronic radiation enteritis (CRE) by observing factors related to the therapeutic effect and adverse reactions of UCB-MNCs in treating CRE.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-75 years, with no restriction on gender;
  • History of pelvic and abdominal radiotherapy;
  • Patients diagnosed with chronic radiation-induced intestinal injury (CRII) via colonoscopy and pathological examination (≥3 months after the end of radiotherapy);
  • Diagnosed with grade 2-3 radiation-induced intestinal injury based on the clinical symptom assessment (RTOG classification) in Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Radiation-Induced Intestinal Injury in China;
  • Poor response to conventional treatment for two weeks, with symptoms showing no remission or progressive aggravation;
  • Well-controlled tumor for ≥3 months;
  • No significant abnormalities in liver and renal function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN); serum creatinine (Cr) and blood urea nitrogen (BUN) ≤ 2 times the upper limit of normal (ULN);
  • Expected lifespan of the subject ≥ 3 months;
  • The patient is informed of the study details and voluntarily signs the informed consent form;
  • Willing and able to receive treatment and complete follow-up in accordance with the protocol requirements, and able to adhere to the doctor's advice for basic treatment.

Exclusion criteria

  • Severe cardiac insufficiency (e.g., NYHA classification Grade Ⅲ or Ⅳ) and uncontrolled hypertension with medication (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 110 mmHg);
  • Positive results for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis;
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≥ 2;
  • Currently participating in another clinical trial or having participated in another clinical trial within 4 weeks;
  • Patients with an allergic diathesis or known allergy to the preparation used in this trial;
  • Patients with comorbid mental illness who are unable to cooperate with treatment;
  • Pregnant or lactating women.

Treatment and study plan

UCB-MNCs

Biological

UCB-MNCs will be administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.

Primary outcomes

  1. Change from baseline Vienna Rectoscopy Score (VRS)

    Time frame: At 3 and 12 months after the last treatment.

    The VRS evaluates four core endoscopic features (mucosal hyperemia/erythema, mucosal ulceration, mucosal fibrosis/stenosis, and telangiectasia), with each feature scored on a 0-3 scale (0 = no abnormality, 3 = severe abnormality). The total VRS score is the sum of scores from the four features, typically ranging from 0 to 12. The total score directly reflects the severity of radiation-induced intestinal injury.

Secondary outcomes

  1. Clinical remission rate

    Time frame: At 1 week, 1 month, 3 months, 6 months, and 12 months after the last treatment.

    Symptoms such as hematochezia and diarrhea will be counted before treatment and at 1 week, 1 month, 3 months, 6 months, and 12 months after the last treatment. The corresponding symptom remission rate will be calculated by comparing with the pre-treatment status.

  2. Change from baseline LENT-SOMA scoring scale

    Time frame: At 3 months and 12 months after the last treatment.

    LENT-SOMA uses a 0-4 grading system for each of the four dimensions (subjective, objective, management, analytic), with scores directly reflecting the severity of radiation-induced tissue injury. A higher LENT-SOMA grade indicates more severe radiation-induced tissue damage.

  3. Change from baseline visual analog scale (VAS)

    Time frame: At 1 week, 1 month, 3 months, 6 months, and 12 months after the last treatment.

    VAS is a simple tool to measure pain extent: it uses a 10-centimeter horizontal line, with "no pain at all" marked at 0 and "worst pain imaginable" at 10. Patients mark a point matching their current pain.

  4. Hemoglobin concentration

    Time frame: Changes in hemoglobin levels will be compared before treatment and at 1 week, 1 month, 3 months, 6 months, and 12 months after the last treatment.

  5. Changes in Intestinal Flora Distribution

    Time frame: At 1 week and 1 month after the last treatment.

    Intestinal flora distribution specifically describes the composition, quantity, and proportional balance of the microbial species.

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Zhejiang Cancer Hospital

Other

Registry information

Official study title

Study on the Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in the Treatment of Chronic Radiation Enteritis

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 16, 2025
Registry last updated
Sep 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.